Research Nester published a report titled “Neuralgia Drugs Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global neuralgia drugs market in terms of market segmentation by type, distribution channel, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global neuralgia drugs market is estimated to occupy a large revenue by growing at a CAGR of ~6% during the forecast period, i.e., 2022 – 2030, owing to the escalating prevalence of trigeminal neuralgia, rising incidences of diabetes and increasing occurrence of multiple sclerosis. Apart from these, rapidly growing geriatric population and surge in development of healthcare infrastructure worldwide is also expected to drive market growth in the coming years.
The market is segmented by type and distribution channel. Based on type, the anticonvulsants segment is anticipated to grab the largest market share during the forecast period on the back of increasing use of carbamazepine for the treatment of neuralgia. Additionally, based on distribution channel, the hospital pharmacies segment is projected to hold the largest share over the forecast period ascribing to the frequent interactions of prescriber and other health professionals are promoted in a hospital facility.
Geographically, the global neuralgia drugs market is segmented into five major regions, namely North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. North America region is evaluated to grab the largest share in the market during the forecast period attributing to the growing awareness regarding several treatment options in the region. Moreover, the market in Asia Pacific is assessed to grow by the highest rate in the future owing to the rising prevalence of diabetes in the region.
The research was global in nature and conducted in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa). In addition, areas like Market size, Y-O-Y growth & Opportunity Analysis, market players competitive study, investment opportunities, demand for future outlook etc. have been covered and displayed in the research report to ensure it dives deep to achieve strategic competitive intelligence in the segment.
Increasing Prevalence of Trigeminal Neuralgia Across the World to Drive Market Growth
As the total number of incidences of diabetes and conditions associated with it, such as migraine, are on a rise, the cases of trigeminal neuralgia are also increasing. Poor lifestyle changes and growing consumption of alcohol are also expected to fuel the occurrence of neuralgia, which in turn is predicted to drive market growth in the near future.
“The Final Report will cover the impact analysis of COVID-19 on this industry.”
However, poor efficacy of various available neuralgia drugs is expected to operate as key restraint to the growth of the global neuralgia drugs market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global neuralgia drugs market which includes company profiling of Pfizer, Inc., Novartis AG, Biogen Inc., Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc., and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global neuralgia drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]